These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 19440002

  • 1. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
    Okamura K, Ito M, Tanaka K, Chinushi M, Adachi T, Mitsuma W, Hirono S, Nakazawa M, Kodama M, Aizawa Y.
    Pharmacology; 2009; 83(6):360-6. PubMed ID: 19440002
    [Abstract] [Full Text] [Related]

  • 2. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M.
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC.
    Bahrudin U, Ikeda N, Utami SB, Maharani N, Morikawa K, Li P, Sobirin MA, Hasegawa A, Sakata S, Endo R, Rifqi S, Shirayoshi Y, Yamamoto K, Ninomiya H, Hisatome I.
    Drug Res (Stuttg); 2013 Oct; 63(10):515-20. PubMed ID: 23740383
    [Abstract] [Full Text] [Related]

  • 4. Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.
    Matsuyama N, Tsutsumi T, Kubota N, Nakajima T, Suzuki H, Takeyama Y.
    Hypertens Res; 2009 Aug; 32(8):721-6. PubMed ID: 19590505
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
    Shinohara K, Hirooka Y, Ogawa K, Kishi T, Yasukawa K, Utsumi H, Sunagawa K.
    Clin Exp Hypertens; 2012 Aug; 34(6):456-62. PubMed ID: 22471901
    [Abstract] [Full Text] [Related]

  • 6. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M.
    Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
    [Abstract] [Full Text] [Related]

  • 7. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K.
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
    [Abstract] [Full Text] [Related]

  • 8. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
    Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M.
    Am J Hypertens; 2009 Feb; 22(2):145-50. PubMed ID: 19057515
    [Abstract] [Full Text] [Related]

  • 9. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
    Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y.
    Kidney Blood Press Res; 2009 Feb; 32(4):239-49. PubMed ID: 19752573
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
    Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, Miwa T, Masuyama T, Yamamoto K, Hori M.
    J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
    [Abstract] [Full Text] [Related]

  • 11. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
    Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H.
    Hypertens Res; 2004 Oct; 27(10):771-9. PubMed ID: 15785013
    [Abstract] [Full Text] [Related]

  • 12. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

  • 13. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
    Guo Q, Minami N, Mori N, Nagasaka M, Ito O, Kurosawa H, Kanazawa M, Kohzuki M.
    Hypertens Res; 2008 Mar; 31(3):525-33. PubMed ID: 18497473
    [Abstract] [Full Text] [Related]

  • 14. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
    Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M.
    J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
    [Abstract] [Full Text] [Related]

  • 15. Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
    Araki S, Hirooka Y, Kishi T, Yasukawa K, Utsumi H, Sunagawa K.
    Hypertens Res; 2009 Dec; 32(12):1091-6. PubMed ID: 19763130
    [Abstract] [Full Text] [Related]

  • 16. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K.
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [Abstract] [Full Text] [Related]

  • 17. Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
    Tada T, Nawata J, Wang H, Onoue N, Zhulanqiqige D, Ito K, Sugimura K, Fukumoto Y, Shimokawa H.
    Cardiovasc Res; 2008 Dec 01; 80(3):346-53. PubMed ID: 18687705
    [Abstract] [Full Text] [Related]

  • 18. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
    Omote Y, Deguchi K, Kono S, Liu W, Kurata T, Hishikawa N, Yamashita T, Ikeda Y, Abe K.
    J Neurosci Res; 2014 Oct 01; 92(10):1330-7. PubMed ID: 24839960
    [Abstract] [Full Text] [Related]

  • 19. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
    Shokoji T, Fujisawa Y, Kiyomoto H, Rahman M, Sun GP, Fan YY, Kimura S, Kohno M, Abe Y, Nishiyama A.
    Hypertens Res; 2005 Dec 01; 28(12):1017-23. PubMed ID: 16671342
    [Abstract] [Full Text] [Related]

  • 20. Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.
    Maeda S, Matsui T, Takeuchi M, Yamagishi S.
    Int J Cardiol; 2011 Jan 21; 146(2):264-6. PubMed ID: 21095028
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.